DAFNA Capital Management LLC
13F Reported Value
ⓘ$524.4M
Holdings
88
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
DAFNA Capital Management LLC disclosed 88 positions worth $524.4M in its Form 13F-HR for Q2 2026, led by $RVMD (Revolution Medicines, Inc.) at 20.1% of the equity portfolio. During the quarter the fund opened 14 new positions and exited 8 — including a new stake in $KYMR and a full exit from $DAWN. The portfolio is most concentrated in Healthcare (91.8% of disclosed assets). All figures are sourced directly from DAFNA Capital Management LLC’s Form 13F-HR filing with the SEC under CIK 1389933.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$105.4M562,630 sh SPDR S&P BIOTECH ETF - ETF
—Quality
$31.1M196,505 sh- —
Quality
$28.5M2,011,952 sh - 18.7
Quality
$23.5M13,680,554 sh - 9.7
Quality
$22.2M318,380 sh - —
Quality
$19.0M739,014 sh - 36.1
Quality
$18.5M497,240 sh - 59.0
Quality
$16.7M597,431 sh - 24.0
Quality
$15.1M250,772 sh - 28.1
Quality
$14.7M171,998 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Revolution Medicines, Inc.$RVMD | — | $105.4M | 562,630 |
| SPDR S&P BIOTECH ETF - ETF | — | $31.1M | 196,505 |
 COMPASS Pathways plc$CMPS | — | $28.5M | 2,011,952 |
 Stereotaxis, Inc.$STXS | 18.7 | $23.5M | 13,680,554 |
 NEKTAR THERAPEUTICS$NKTR | 9.7 | $22.2M | 318,380 |
 Denali Therapeutics Inc.$DNLI | — | $19.0M | 739,014 |
 IDEAYA Biosciences, Inc.$IDYA | 36.1 | $18.5M | 497,240 |
 AtriCure, Inc.$ATRC | 59.0 | $16.7M | 597,431 |
 Xenon Pharmaceuticals Inc.$XENE | 24.0 | $15.1M | 250,772 |
 CYTOKINETICS INC$CYTK | 28.1 | $14.7M | 171,998 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of DAFNA Capital Management LLC's 88 positions.
Showing top 10 of 88 holdings.
Sector Allocation
Healthcare
$481.3M
Other
$43.1M
Full Holdings — DAFNA Capital Management LLC (Q2 2026)
All 88 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RVMD | Revolution Medicines, Inc. | $105.4M | 20.1% | -3% | — |
| 2 | — | SPDR S&P BIOTECH ETF - ETF | $31.1M | 5.9% | -38% | — |
| 3 | $CMPS | COMPASS Pathways plc | $28.5M | 5.4% | -17% | — |
| 4 | $STXS | Stereotaxis, Inc. | $23.5M | 4.5% | +0% | 18.7 |
| 5 | $NKTR | NEKTAR THERAPEUTICS | $22.2M | 4.2% | +93% | 9.7 |
| 6 | $DNLI | Denali Therapeutics Inc. | $19.0M | 3.6% | +132% | — |
| 7 | $IDYA | IDEAYA Biosciences, Inc. | $18.5M | 3.5% | +4% | 36.1 |
| 8 | $ATRC | AtriCure, Inc. | $16.7M | 3.2% | +0% | 59 |
| 9 | $XENE | Xenon Pharmaceuticals Inc. | $15.1M | 2.9% | +0% | 24 |
| 10 | $CYTK | CYTOKINETICS INC | $14.7M | 2.8% | -21% | 28.1 |
| 11 |  $RCUS | Arcus Biosciences, Inc. | $13.6M | 2.6% | -0% | 8.5 |
| 12 |  $ASND | Ascendis Pharma A/S | $12.9M | 2.5% | -99% | 44.8 |
| 13 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $9.7M | 1.9% | -18% | 76.5 |
| 14 |  $AXGN | Axogen, Inc. | $9.7M | 1.8% | -16% | 40.8 |
| 15 |  $PODD | INSULET CORP | $9.4M | 1.8% | +469% | 71.3 |
| 16 |  $EWTX | Edgewise Therapeutics, Inc. | $9.2M | 1.8% | +102% | — |
| 17 |  $BCAX | Bicara Therapeutics Inc. | $8.5M | 1.6% | -32% | — |
| 18 | — | ISHARES NASDAQ BIOTECH INDX - ETF | $8.1M | 1.5% | -31% | — |
| 19 |  $SNDX | Syndax Pharmaceuticals Inc | $7.3M | 1.4% | +54% | 33.8 |
| 20 |  $MPLT | MapLight Therapeutics, Inc. | $6.1M | 1.2% | +0% | — |
| 21 |  $LRMR | Larimar Therapeutics, Inc. | $6.1M | 1.2% | -1% | — |
| 22 |  $IPSC | Century Therapeutics, Inc. | $5.9M | 1.1% | -1% | 33.5 |
| 23 |  $DXCM | DEXCOM INC | $5.8M | 1.1% | +0% | 76 |
| 24 |  $IMVT | Immunovant, Inc. | $5.8M | 1.1% | -1% | — |
| 25 |  $INGN | Inogen Inc | $5.5M | 1.0% | +0% | 31.9 |
| 26 |  $TNDM | TANDEM DIABETES CARE INC | $5.4M | 1.0% | +0% | 42.8 |
| 27 |  $ALKS | Alkermes plc. | $5.3M | 1.0% | -27% | — |
| 28 |  $STOK | Stoke Therapeutics, Inc. | $4.3M | 0.8% | +0% | 24.9 |
| 29 |  $ALLO | Allogene Therapeutics, Inc. | $4.2M | 0.8% | +46% | 33.9 |
| 30 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $4.0M | 0.8% | -7% | 53.2 |
| 31 | — | LAKEFRONT BIOTHERAPEUTICS NV - SPON ADR | $3.9M | 0.7% | +0% | — |
| 32 |  $KIDS | ORTHOPEDIATRICS CORP | $3.6M | 0.7% | +98% | 37.8 |
| 33 |  $HELP | CYBIN INC. | $3.4M | 0.7% | +3% | — |
| 34 |  $RAPP | Rapport Therapeutics, Inc. | $3.1M | 0.6% | +0% | — |
| 35 |  $KYMR | Kymera Therapeutics, Inc. | $3.1M | 0.6% | NEW | 28.4 |
| 36 |  $PRQR | ProQR Therapeutics N.V. | $2.8M | 0.5% | -2% | — |
| 37 |  $NGNE | Neurogene Inc. | $2.8M | 0.5% | +57% | 27.4 |
| 38 |  $ANL | Adlai Nortye Group Ltd. | $2.8M | 0.5% | NEW | — |
| 39 |  $PRCT | PROCEPT BioRobotics Corp | $2.7M | 0.5% | +0% | 33.3 |
| 40 |  $AQST | Aquestive Therapeutics, Inc. | $2.7M | 0.5% | +75% | 14.5 |
| 41 |  $CLDX | Celldex Therapeutics, Inc. | $2.5M | 0.5% | +0% | 8.4 |
| 42 |  $GPCR | Structure Therapeutics Inc. | $2.5M | 0.5% | +0% | — |
| 43 |  $ALGN | ALIGN TECHNOLOGY INC | $2.4M | 0.5% | -7% | 58.9 |
| 44 |  $VKTX | Viking Therapeutics, Inc. | $2.3M | 0.4% | +0% | — |
| 45 |  $NGEN | NERVGEN PHARMA CORP. | $2.2M | 0.4% | NEW | — |
| 46 |  $BHVN | Biohaven Ltd. | $2.0M | 0.4% | -84% | — |
| 47 |  $MAZE | Maze Therapeutics, Inc. | $1.9M | 0.4% | +86% | 10.3 |
| 48 |  $ALEC | Alector, Inc. | $1.8M | 0.3% | +0% | 10.9 |
| 49 |  $LXEO | Lexeo Therapeutics, Inc. | $1.8M | 0.3% | +0% | — |
| 50 |  $PROF | Profound Medical Corp. | $1.7M | 0.3% | -1% | — |
| 51 |  $RNA.R1599901 | Avidity Biosciences, Inc. | $1.7M | 0.3% | NEW | — |
| 52 |  $ANNX | Annexon, Inc. | $1.7M | 0.3% | +153% | — |
| 53 |  $CTMX | CytomX Therapeutics, Inc. | $1.6M | 0.3% | +91% | 8.7 |
| 54 |  $RARE | Ultragenyx Pharmaceutical Inc. | $1.6M | 0.3% | -23% | 34.2 |
| 55 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $1.5M | 0.3% | NEW | — |
| 56 |  $DSGN | Design Therapeutics, Inc. | $1.5M | 0.3% | NEW | — |
| 57 |  $FATE | FATE THERAPEUTICS INC | $1.4M | 0.3% | -5% | 9.2 |
| 58 |  $MDWD | MediWound Ltd. | $1.4M | 0.3% | +0% | — |
| 59 |  $KURA | Kura Oncology, Inc. | $1.3M | 0.3% | -49% | 27.6 |
| 60 |  $SPRY | ARS Pharmaceuticals, Inc. | $1.3M | 0.3% | +18% | 20.3 |
| 61 |  $MLYS | Mineralys Therapeutics, Inc. | $1.2M | 0.2% | +16% | — |
| 62 |  $IMTX | Immatics N.V. | $1.2M | 0.2% | -48% | — |
| 63 |  $TELA | TELA Bio, Inc. | $1.1M | 0.2% | +0% | 25.2 |
| 64 |  $PYPD | PolyPid Ltd. | $1.1M | 0.2% | +0% | — |
| 65 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $1.0M | 0.2% | NEW | — |
| 66 |  $INSP | Inspire Medical Systems, Inc. | $811,902 | 0.1% | +0% | 63.7 |
| 67 |  $ACET | Adicet Bio, Inc. | $810,536 | 0.1% | +0% | — |
| 68 |  $SPTX | Seaport Therapeutics, Inc. | $703,728 | 0.1% | NEW | — |
| 69 |  $MBX | MBX Biosciences, Inc. | $651,857 | 0.1% | -93% | — |
| 70 |  $BNTX | BioNTech SE | $651,350 | 0.1% | +0% | — |
| 71 |  $ARTV | Artiva Biotherapeutics, Inc. | $650,880 | 0.1% | NEW | 9.7 |
| 72 |  $PLRX | PLIANT THERAPEUTICS, INC. | $555,180 | 0.1% | +0% | — |
| 73 |  $SCYX | SCYNEXIS INC | $552,983 | 0.1% | -88% | — |
| 74 |  $EDIT | Editas Medicine, Inc. | $552,323 | 0.1% | NEW | 33.4 |
| 75 |  $OBIO | Orchestra BioMed Holdings, Inc. | $547,319 | 0.1% | +0% | 32 |
| 76 |  $FHTX | Foghorn Therapeutics Inc. | $545,872 | 0.1% | +0% | 16.1 |
| 77 |  $ARAY | ACCURAY INC | $433,235 | 0.1% | +0% | 23 |
| 78 |  $FIXX | Q32 Bio Inc. | $419,095 | 0.1% | NEW | 36.4 |
| 79 |  $NVCT | Nuvectis Pharma, Inc. | $367,800 | 0.1% | NEW | — |
| 80 |  $CGEN | COMPUGEN LTD | $360,016 | 0.1% | -35% | — |
| 81 |  $IBIO | iBio, Inc. | $297,593 | 0.1% | -12% | 10.4 |
| 82 |  $AUTL | Autolus Therapeutics plc | $286,906 | 0.1% | +0% | — |
| 83 |  $BCYC | BICYCLE THERAPEUTICS PLC | $273,446 | 0.1% | +0% | — |
| 84 |  $TNYA | Tenaya Therapeutics, Inc. | $221,730 | 0.0% | NEW | — |
| 85 |  $VRCA | Verrica Pharmaceuticals Inc. | $145,350 | 0.0% | -85% | 32.7 |
| 86 |  $ENGN | enGene Therapeutics Inc. | $129,145 | 0.0% | -60% | — |
| 87 |  $KARD | Kardigan, Inc. | $119,250 | 0.0% | NEW | — |
| 88 |  $ADCT | ADC Therapeutics SA | $82,477 | 0.0% | +7% | 21.8 |
New Positions (14)
$KYMR Kymera Therapeutics, Inc.$3.1M$ANL Adlai Nortye Group Ltd.$2.8M$NGEN NERVGEN PHARMA CORP.$2.2M$RNA.R1599901 Avidity Biosciences, Inc.$1.7M$EPRX EUPRAXIA PHARMACEUTICALS INC.$1.5M$DSGN Design Therapeutics, Inc.$1.5M$CRBP Corbus Pharmaceuticals Holdings, Inc.$1.0M$SPTX Seaport Therapeutics, Inc.$703,728$ARTV Artiva Biotherapeutics, Inc.$650,880$EDIT Editas Medicine, Inc.$552,323$FIXX Q32 Bio Inc.$419,095$NVCT Nuvectis Pharma, Inc.$367,800$TNYA Tenaya Therapeutics, Inc.$221,730$KARD Kardigan, Inc.$119,250
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for DAFNA Capital Management LLC including:
Track DAFNA Capital Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for DAFNA Capital Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: DAFNA Capital Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For DAFNA Capital Management LLC (SEC CIK: 1389933), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in DAFNA Capital Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.